Menlo Park, CA, July 27, 2022 – Dr. Maky Zanganeh, DDS, MBA, a recognized leader in the healthcare industry, is honored to announce that she has been appointed as Summit Therapeutics (NASDAQ: SMMT) Co-Chief Executive Officer & President, effective immediately.
As published by Summit Therapeutics:
Menlo Park, California, July 26, 2022 – Summit Therapeutics Inc. (NASDAQ: SMMT) announces that Dr. Maky Zanganeh, DDS, MBA, has been appointed as Co-Chief Executive Officer & President, effective immediately. Dr. Zanganeh was formerly the Company’s Chief Operating Officer having served in that capacity since she joined the Company as an employee in November 2020 and remains a member of the Company’s Board of Directors.
“Maky defines what it means to be a great leader,” said Robert W. Duggan, Executive Chairman and Chief Executive Officer of Summit. “We have assembled a world-class leadership team here at Summit and have guided a group of accomplished executives into the next chapter of our growth. As we seek to expand our pipeline through business development activities, as well as chart the path forward with our current pipeline drug candidates, there is no one, exemplified by Maky’s past successes, that is better prepared to lead us through this journey. I am proud to serve alongside Maky and partner with her expertise as the co-leaders of this organization built with the purpose of improving the condition of overall human health.”
Prior to joining Summit, Dr. Zanganeh founded Maky Zanganeh and Associates in 2015, and from 2008 to 2015, she held multiple leadership positions at Pharmacyclics, Inc., culminating in her role as Chief Operating Officer. As COO of Pharmacyclics, she oversaw all clinical development, regulatory, research, and commercial functions in addition to all business-related matters. Dr. Zanganeh played a key role in the over $1 billion collaboration and a license deal for ibrutinib with Janssen Biotech, Inc. in 2011, and the subsequent sale of Pharmacyclics to AbbVie Inc. for $21 billion in 2015. She is currently a board member for Pulse Biosciences, Inc. Dr. Zanganeh received her DDS from the Louis Pasteur University (France) and her MBA from Schiller International University (France).
Earlier this year, Dr. Zanganeh was an honored speaker at the United Nations’ 7th Anniversary of the February 11 Global Movement celebrating women and girls in science. Dr. Zanganeh was also named a “Top 10 Most Influential COOs of 2021” by Industry Era magazine. She earned the She earned the Fierce Biotech “Top Women in Biotech 2013” award and was a finalist for the Ernst & Young “Entrepreneur of the Year” award in 2013. She is also a published author, recently releasing her book entitled, The Magic of Normal.
“I am truly honored to be elevated to the Co-CEO role at Summit,” stated Dr. Zanganeh. “The trust shown in Bob and me by many of our former executives at past adventures to join us at Summit, combined with our new talented leaders working with us for the first time, speaks volumes as to the impact we can accomplish for patients. Our mission-driven culture to always consider how we can help patients in every decision that we make will ultimately guide us to making a meaningful difference in resolving high unmet needs in oncology and infectious diseases. I am humbled by the opportunity to co-lead our impressive group of accomplished executives and teammates as we seek to expand our pipeline and achieve this goal.
To view the entire press release: Summit Therapeutics Appoints Dr. Maky Zanganeh as Co-CEO & President | Summit Therapeutics (summittxinc.com)
Biography:
Dr. Maky Zanganeh, DDS, MBA, is a recognized leader in the healthcare industry. Dr. Zanganeh is currently the Co-CEO & President, and member of the board at Summit Therapeutics (NASDAQ: SMMT), a company committed to leadership in resolving serious, unmet medical needs for the betterment of overall human health.
Prior to joining Summit, Dr Zanganeh, as Chief Operating Officer at Pharmacyclics, played a key role in leading a struggling biotech company to a billon dollar collaboration and license deal for ibrutinib with Johnson & Johnson in 2011 and the subsequent sale of the company for $21 billion dollars for 50% ownership of ibrutinib in 2015 to AbbVie Inc. This was the second largest biopharma sale ever in the industry at that time. The deal with Johnson & Johnson received the award of the “Best Biotech Transaction” in 2011. Under her leadership in 2015, Pharmacyclics was also awarded the prestigious Prix Galien for “Best Pharmaceutical Agent”. This award is the biomedical industry’s highest accolade and recognizes outstanding achievements in the development of new therapies.
Dr. Zanganeh is an honored speaker of the United Nations, recently speaking during the closing ceremony during the United Nations February 11 Global Movement held on February 11, 2022. Dr. Zanganeh was President of EMEA / Global VP of Training and Education for Computer Motion, Inc. (Pioneers in Robotic Surgery) which later merged with Intuitive, Inc. (ISRG) company in June 2003.
Dr. Zanganeh was awarded her DDS (Dental Degree of Surgery) from the Louis Pasteur University, France and an MBA from Schiller International University, France. She is fluent in French, German, Farsi, and English. Dr Zanganeh earned the Fierce Biotech “2013 Top women in biotech” award, and the E&Y company “Entrepreneur of the Year” 2013 award. She is also a published author, recently releasing her book entitled The Magic of Normal.
To order Maky Zanganeh’s Book The Magic of Normal
Amazon
US: The Magic of Normal: Zanganeh, Dr Maky, Berman, Cheryl: 9781662466694: Amazon.com: Books
UK: The Magic of Normal: Amazon.co.uk: Zanganeh, Dr. Maky, Berman, Cheryl: 9781662466694: Books
Barnes and Nobel
The Magic of Normal by Dr. Maky Zanganeh, Paperback | Barnes & Noble® (barnesandnoble.com)
To Contact Dr. Maky Zanganeh
info@mzanganeh.com